Board of Directors
Sylvie Grégoire, PharmD
Co-Founder, Executive Chair
Sylvie Grégoire is an industry veteran with 30 years of industry experience. She is the former president of Human Genetic Therapies at Shire Pharmaceuticals, a position she held from 2007 to 2013. Previously, she was executive chairman of IDM Pharma Inc., and president and chief executive officer of GlycoFi Inc. From 1995 until 2003, Sylvie held various leadership positions at Biogen most recently as executive vice president of Technical Operations. Prior to Biogen, she was at Merck and Co, in clinical research and regulatory affairs for a period of 8 years.
Sylvie currently serves as Chair of the Board of Directors at Corvidia, Inc., and is a member of the Board of Directors of Novo Nordisk A/S and Perkin Elmer Corporation. She received her PharmD degree from the State University of New York at Buffalo, a Bachelors degree in Pharmacy from Laval University, Canada, and a Science College degree from Seminaire de Sherbrooke, Canada.
John Alam, MD
Co-Founder and Chief Executive Officer
John Alam is an industry leader in translational medicine and has over 25 years of experience in creating value to help build companies through clinical development success. Until May 2014, he was therapeutic area head for diseases of aging at Sanofi, where he led all discovery and development activities directed at Alzheimer’s disease, as well as a number of other age-related diseases including sarcopenia/frailty, osteoarthritis, chronic pain and many others. From 1997 to 2008, he held positions of increasing responsibility at Vertex Pharmaceuticals, including Chief Medical Officer and Executive Vice President, Medicines Development. At Vertex, he played major roles in the development of novel innovative medicines for HIV, Hepatitis C and Cystic Fibrosis. Prior to Vertex, Alam led clinical development of Avonex (interferon beta-1a) for multiple sclerosis at Biogen from 1991 to 1997.
John is a member of the board of directors of the Alliance for Aging Research (AAR), a Washington, D.C. based non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. He received a MD from Northwestern University School of Medicine and a SB in chemical engineering from the Massachusetts Institute of Technology. In addition, he completed an internal medicine residency at Brigham and Women’s Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute.
Tatjana May is a non-executive member of the board of EIP Pharma. She is an experienced General Counsel with over 25 years of legal experience and substantial knowledge and understanding of the pharmaceutical sector. She brings with her extensive legal and governance experience including working in a dual listed environment and managing M&A activity and litigation in both the EU and the USA. Between 2001 and 2015, Tatjana May was at Shire plc where she served as General Counsel and Company Secretary and was on Shire’s Executive Committee. Prior to this Tatjana worked at AstraZeneca plc, where her last position was Assistant General Counsel. Tatjana’s early career was spent at Slaughter and May in London.
Tatjana is a non-executive director at Indivior, a UK pharmaceutical company focused on finding therapies for the treatment of opioid addiction. She obtained her Bachelor of Laws from Southampton University.
Jeff Poulton is a non-executive member of the board of EIP Pharma. He was recently appointed as Chief Financial Officer of Alnylam Pharmaceuticals. Previously, he served as Chief Financial Officer at Indigo Agriculture, a plant microbiome company in Boston, from January 2018 to May 2019.
Frank Zavrl is a non-executive member of the board of EIP Pharma. He has substantial experience in investment in the pharma and biotechnology industry. From 2002 to 2011, he was a Partner at Adage Capital Management, L.P., specializing in biotechnology investments. Prior to joining Adage Capital, Frank was a Portfolio Manager from 1999 to 2002 at Merlin Biomed, a healthcare investment group. From 1998 to 1999, he was an analyst at Scudder Kemper Investments Inc., focusing on biotechnology investments.
Since 2015, Frank has been a member of the board of Puma Biotechnology, a company focused on the treatment of cancer. He received an MBA from the Tuck School of Business at Dartmouth College and a BS in Biochemistry from the University of California, Berkeley.
EIP Pharma in the News
EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer’s Disease
November 7, 2019
EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)